4.1 Article

Prevalence of Anxiety and Depression in Patients with Inflammatory Bowel Disease

出版社

HINDAWI LTD
DOI: 10.1155/2017/6496727

关键词

-

资金

  1. Janssen
  2. Abbvie
  3. GSK
  4. BMS
  5. Amgen
  6. Genentech
  7. Merck
  8. RedHill Biopharma
  9. BI
  10. Qu Biologic
  11. Celgene
  12. Alvine

向作者/读者索取更多资源

Background. Inflammatory bowel disease (IBD) patients are not routinely screened for depression and anxiety despite knowledge of an increased prevalence in people with chronic disease and negative effects on quality of life. Methods. Prevalence of anxiety and depression was assessed in IBD outpatients through retrospective chart review. The presence of anxiety and/ or depression was determined using the Patient Health Questionnaire-9 and Generalized Anxiety Disorder-7 self-report questionnaires or by diagnosis through psychiatric interview. Patient demographics, disease characteristics, and medication information were also collected. Multivariable analysis was used to determine associations between patient factors and depression and anxiety. Results. 327 patient charts were reviewed. Rates of depression and anxiety were found to be 25.8% and 21.2%, with 30.3% of patients suffering fromdepression and/ or anxiety. Disease activity was found to be significantly associated with depression and/ or anxiety (p = 0.01). Females were more likely to have anxiety (p = 0.01). Conclusion. A significant proportion of IBD patients suffer from depression and/or anxiety. The rates of these mental illnesses would justify screening and referral for psychiatric treatment in clinics treating this population. Patients with active disease are particularly at risk for anxiety and depression.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据